Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Clinical trial Stories

2014-02-04 08:34:50

LONDON, Feb. 4, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013 Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013" provides data on the Chemotherapy Induced Nausea and Vomiting clinical trial scenario. This report...

2014-02-04 04:22:06

- Expands Presence to Meet Demand for EDC, CTMS and IRT Technologies - NEWTOWN, Pa., Feb. 4, 2014 /PRNewswire/ -- BioClinica(®), Inc., the global provider of clinical trial management solutions, today announced that Europe was the fastest growing geographic region in 2013 for its eClinical technology products. The Company plans continued investments in its European workforce in the areas of operations and sales, potentially doubling its European eClinical presence in 2014. The...

2014-02-03 12:29:45

LONDON, February 3, 2014 /PRNewswire/ -- Ergomed Clinical Research Ltd, a leading clinical development company working with biotechnology and pharmaceutical companies, today announces that it has entered into an agreement with Ferrer, a privately-held Spanish pharmaceutical company, to support further clinical studies of Lorediplon in patients with insomnia. Ferrer also announced it is collaborating with Ildong Pharmaceuticals Co Ltd, Korea. Ergomed is working with...

2014-02-03 12:29:34

RESEARCH TRIANGLE PARK, N.C., Feb. 3, 2014 /PRNewswire/ -- Dr. Renu Razdan, Vice President ACRO India and also the Chief Operating Officer, Max Neeman Medical International welcomes the new timelines and guidelines set up by the Drug Controller General of India [DCGI] for approval of clinical trials. The Drug regulatory authority in India has provided written confirmation to the pharmaceutical industry and Investigators that, clinical trial approval will be given within 180 days of...

2014-02-03 12:29:31

Clinical research team meets with principal investigators in St Petersburg as a clinical trial of the first tau aggregation inhibitor (TAI) in Phase 3, aimed at halting the progression of Alzheimer's, gets underway in Russia ALBANY, N.Y., Feb. 3, 2014 /PRNewswire/ -- A doctor-and-nurse team from the Neurological Associates of Albany clinic will travel to St Petersburg, Russia, next month to meet with clinical research doctors about TauRx Therapeutics' global Phase 3 clinical trial...

2014-02-03 12:28:23

LONDON, Feb. 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Heart Transplantation Global Clinical Trials Review, H2, 2013Heart Transplantation Global Clinical Trials Review, H2, 2013 SummaryGlobalData's clinical trial report, "Heart Transplantation Global Clinical Trials Review, H2, 2013" provides data on the Heart Transplantation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on...

2014-02-03 12:26:49

LONDON, Feb. 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Inflammation Global Clinical Trials Review, H2, 2013 Inflammation Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, "Inflammation Global Clinical Trials Review, H2, 2013" provides data on the Inflammation clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inflammation. It includes an...

2014-02-03 12:26:46

First pharmacogenomics study launches in diverse pediatric population BOSTON, Feb. 3, 2014 /PRNewswire-USNewswire/ -- Aiming to reduce adverse drug reactions--which affect some 70,000 children annually in the U.S.(1)--a study at Boston Children's Hospital, in partnership with the Medical College of Wisconsin (MCW) and the Children's Hospital of Wisconsin Research Institute, is using genetic information to predict children's reactions to medications, ultimately enabling clinicians to...

2014-02-03 08:26:56

CAMBRIDGE, Mass., Feb. 3, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetically defined cancers, today announced that it has commenced an underwritten public offering of 4,192,679 shares of its common stock. The offering is expected to consist of 3,000,000 shares to be offered by Epizyme and 1,192,679 shares to be offered by...

2014-01-31 16:23:54

DUBLIN, January 31, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jnqpps/emrs_and_clinical) has announced the addition of the "EMRs and Clinical Research: Current and Potential Impact" [http://www.researchandmarkets.com/research/jnqpps/emrs_and_clinical ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) In this report, ISR leverages the insights and real-world experiences...